Explore the compound
Quick Facts
Mechanism of Action
Formulation: This premixed research formulation contains BPC 157 10 mg, GHK-CU 50 mg, TB500 10 mg, KPV 10 mg.
Evidence context: Evidence for individual components and evidence for the combined formulation are tracked separately; findings for one component should not be assumed to establish effects for the mixture.
- Supports collagen, elastin, and extracellular-matrix signaling in skin and tissue research [1].
- Associated with wound-repair and tissue-remodeling pathways in biomedical literature [1].
- Commonly discussed for skin firmness, texture, and appearance-support benefits tied to copper-peptide biology [1].
- Supports antioxidant and anti-inflammatory pathway research in cellular and tissue models [3].
Blend Composition
Listed ingredient quantities represent the contents of the full vial, not an amount to administer. This formulation is supplied as a liquid; no reconstitution is needed.
| Ingredient | Listed quantity per vial |
|---|---|
| BPC 157 | 10 mg |
| GHK-CU | 50 mg |
| TB500 | 10 mg |
| KPV | 10 mg |
Research Applications & Context
GHK-Cu protocol overview: tissue-remodeling and skin-support research model using 3 mL reconstitution planning.
Research Dosage Information
Reported research quantities and their source context. These are not recommendations, and source status varies.
Scroll the table horizontally to read every column. Select a row to inspect it in the calculator.
Community-reported research schedule; not independently clinically validated.
| Phase | Reported Amount | Frequency | Draw Units | Cycle | Notes | Calculator |
|---|---|---|---|---|---|---|
| Weeks 1-2 | 2 mg total (GHK-Cu 1.25 mg + 0.25 mg each of three others) | Once daily | Select a vial | Weeks 1-2 | KLOW 80 mg blend: weekly steps (total compound mass) | |
| Weeks 3-4 | 4 mg total (GHK-Cu 2.5 mg + 0.5 mg each of three others) | Once daily | Select a vial | Weeks 3-4 | KLOW 80 mg blend: weekly steps (total compound mass) | |
| Weeks 5-8 | 6 mg total (GHK-Cu 3.75 mg + 0.75 mg each of three others) | Once daily | Select a vial | Weeks 5-8 | KLOW 80 mg blend: weekly steps (total compound mass) | |
| Weeks 9-12 | 4 mg total (GHK-Cu 2.5 mg + 0.5 mg each of three others) | Once daily | Select a vial | Weeks 9-12 | KLOW 80 mg blend: weekly steps (total compound mass) |
Dosing Protocol & Schedule
Community-reported research schedules, not clinically validated protocols. Select a reported scenario and duration to calculate mathematical quantities.
| Period | Research Dose | Frequency | Total Injections | Total amount | Volume per entry | U-100 equivalent |
|---|
Strength changes affect volume and supplies, not the underlying community-reported quantities. Figures exceeding the selected syringe capacity are flagged; they are not instructions for splitting administrations.
Plan a Regimen Schedule
Save the selected research protocol to your private calendar. Scheduled entries never create Dose Logs.
Reconstitution Calculator
Select the vial strength you are examining. The reference chart displays examples, not recommended preparation volumes or validated protocols.
Reconstitution Reference Chart
Hypothetical volume comparisons for the selected vial. No particular volume is endorsed, and vial capacity, solubility, excipients and product-specific instructions are not established by this table.
| Example volume | Calculated concentration | Calculator |
|---|---|---|
| 1 mL | — | |
| 2 mL | — | |
| 3 mL | — | |
| 4 mL | — | |
| 5 mL | — |
Choose a compatible dry vial to see reference concentrations.
Research-only mathematical comparisons; not instructions to compound, prepare, or administer peptides. Community-reported protocols are not clinically validated by inclusion here.
Supplies Needed — Estimate
Select a vial strength and an example reconstitution volume below. Counts use only the checked, computable rows above; they are not product-specific sterility, compatibility, or stability guidance.
Select a compatible vial and volume below to view quantities.
Educational and entertainment purposes only. Research use only; not for human or animal administration. Pad counts assume two per Total entry; syringe counts include additional containers where a single entry exceeds the selected syringe capacity. Vial totals assume full theoretical recovery and do not account for dead volume, spoilage, asepsis, expiration, potency, route, or beyond-use dating. These figures are not a recommended supplies list for an actual procedure.
Published References (0 identified)
A recorded identifier identifies a publication; it does not establish that its claims have been independently verified.
Research indexes & other source links
Searches, registries and unverified source records are discovery resources, not verified published studies.
- PubMed.gov biomedical literature: KLOW Blend View source ↗ PubMed index/search · Source link recorded; claim verification separate
- ClinicalTrials.gov study registry: KLOW Blend View source ↗ ClinicalTrials.gov registry/search · Source link recorded; claim verification separate
- NIH/NCBI all-databases search: KLOW Blend View source ↗ NCBI database/search · Source link recorded; claim verification separate
- PubChem / NIH compound record search: KLOW Blend View source ↗ PubChem database/search · Source link recorded; claim verification separate
Peptide Research Collection Library